• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Platelet Count Rose Rapidly After Caplacizumab in Refractory iTTP Case

by
November 11, 2026
in Health
Reading Time: 2 mins read
0
Platelet Count Rose Rapidly After Caplacizumab in Refractory iTTP Case

Platelet Count Rose Rapidly After Caplacizumab in Refractory iTTP Case

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A short course of caplacizumab rapidly restored platelet levels in a patient with plasma-exchange-refractory immune-mediated thrombotic thrombocytopenic purpura, according to a case report and focused literature review published by clinicians in mainland China. While caplacizumab has transformed the management of acute immune-mediated thrombotic thrombocytopenic purpura internationally, clinical experience with the agent in mainland China has remained limited.

The case report details the clinical trajectory of a 53-year-old woman presenting with Sjögren’s disease and acute immune-mediated thrombotic thrombocytopenic purpura complicated by cerebral infarctions. Initial management consisted of corticosteroids, two early doses of rituximab, and more than ten sessions of therapeutic plasma exchange. Despite these standard interventions, the patient failed to achieve a sustained platelet response, satisfying traditional clinical criteria for therapeutic plasma exchange-refractory disease.

Following the failure of frontline therapy, clinicians administered five daily doses of caplacizumab. The treatment prompted a rapid hematologic response, with the patient’s platelet count rising sharply to 631 × 10⁹/L. Subsequent caplacizumab doses were withheld due to clinical safety concerns regarding the marked platelet increase, alongside the unavailability of additional drug supplies.

Therapeutic plasma exchange was also terminated following the caplacizumab course due to a plasma shortage. Laboratory monitoring demonstrated that the patient’s ADAMTS13 activity reached 72.73% during therapeutic plasma exchange but dropped below 10% after exchange cessation. After administering two additional doses of rituximab, the patient’s ADAMTS13 activity recovered, and she maintained clinical remission through September 2026, encompassing 18 months of post-discharge follow-up.

Alongside the patient report, the authors conducted a focused review of adult patients with immune-mediated thrombotic thrombocytopenic purpura treated with therapeutic plasma exchange and immunosuppressive therapy. Their evaluation revealed that successful early discontinuation of caplacizumab was most consistently associated with serial ADAMTS13 recovery.

The authors noted that although the patient’s clinical course is consistent with a rapid platelet response following the addition of caplacizumab to standard treatment, the case does not establish that a short course is sufficient or that it reduces bleeding risk. In healthcare settings facing restricted drug access or reimbursement constraints, the authors concluded that shorter courses warrant prospective evaluation alongside standard immunosuppression, serial ADAMTS13 monitoring, close clinical surveillance, and access to rescue therapy.

The case report and literature synthesis, published in Frontiers in Cardiovascular Medicine under the Thrombosis and Haemostasis section, was authored by Xiaoyan Huang, Ling Wu, and Lijun Zhang. The clinicians, affiliated with Shenzhen Hospital at The University of Hong Kong and the Shenzhen Clinical Research Center for Rare Diseases, documented an early clinical application of caplacizumab in mainland China that preceded another detailed report from the region.

Subject of Research: Caplacizumab treatment for refractory immune-mediated thrombotic thrombocytopenic purpura

Article Title: Case Report: Early Chinese experience with caplacizumab for plasma-exchange-refractory immune-mediated TTP and a focused review of short-course treatment

Article References: Huang, X., Wu, L., & Zhang, L. (2026). Case Report: Early Chinese experience with caplacizumab for plasma-exchange-refractory immune-mediated TTP and a focused review of short-course treatment. Frontiers in Cardiovascular Medicine, 13, Article 2020504. https://doi.org/10.3389/fcvm.2026.2020504

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.2020504

Keywords: Caplacizumab, Immune-mediated thrombotic thrombocytopenic purpura, ADAMTS13 activity, Therapeutic plasma exchange, Sjögren's disease, Rituximab, Platelet response, Cerebral infarction, Corticosteroids, TPE-refractory disease, Short-course treatment, Plasma shortage, Clinical remission, Serial ADAMTS13 monitoring, Shenzhen Hospital, Thrombosis and haemostasis, Rare diseases

News Source: Ophelia Keating. (November 11, 2026). Platelet Count Rose Rapidly After Caplacizumab in Refractory iTTP Case. Scienmag.

Tags: ADAMTS13 activitycaplacizumabcerebral infarctionclinical remissioncorticosteroidsImmune-mediated thrombotic thrombocytopenic purpuraPlasma shortagePlatelet responserare diseasesrituximabSerial ADAMTS13 monitoringShenzhen HospitalShort-course treatmentSjögren's diseasetherapeutic plasma exchangeThrombosis and haemostasisTPE-refractory disease
Share12Tweet7Share2ShareShareShare1

Related Posts

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

November 19, 2026
Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

November 19, 2026

Investigational mRNA Flu Vaccine Generates Dual Antigen Immunity in Phase Two Trial

November 19, 2026

Decision Model Defines Economic Benchmarks for Breast Cancer Psychosocial Rehabilitation

November 19, 2026

POPULAR NEWS

  • Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    29 shares
    Share 12 Tweet 7
  • Narrative Review Identifies Systematic Bias and Privacy Risks Across AI Electrocardiography Protocols

    29 shares
    Share 12 Tweet 7
  • Landscape Integrated Farming Framework Links Cross-Farm Resources to Enhance Climate Resilience

    29 shares
    Share 12 Tweet 7
  • Machine Learning Matches Traditional Time Series in Forecasting Tanzanian Sisal Exports

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Analyzes Adaptive Rollout of Molecular Tuberculosis Tests Across the Philippines

Exercise Benefits for Psychological Distress in Lung Cancer Remain Highly Uncertain

Study Quantifies Multidisciplinary Clinical Burden in Von Hippel-Lindau Central Nervous System Tumors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.